Back

Subcutaneous implantable cardioverter defibrillator in pediatric and young adults: an analysis from the European SIDECAR Registry

31 March 2025 (12:30 - 13:15)
Organised by: Logo
Congress Presentation Part of: Device therapy (2) Device Treatment EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Massimo Stefano Silvetti

Bambino Gesu Pediatric Hospital, Rome (Italy)

6 More presentations in this session

Presentation thumbnail
Bidirectional interaction between implantable cardioverter-defibrillator therapy and mental disorders: nationwide cohort study
Doctor J. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Deprivation and device therapy: understanding the impact of socioeconomic status on ICD therapy outcomes
Mr C. Monkhouse (London, GB)
Abstract Slides Video
Presentation thumbnail
Predictors of syncope recurrence in reflex syncope patients with dual-chamber pacemakers with anti-reflex functionality
Doctor T. Vo (Ho Chi Minh, VN)
Abstract Slides Video
Presentation thumbnail
Implantable cardioverter defibrillator resistant mortality in ischemic and dilated cardiomyopathy across therapeutic eras: a single, tertiary center experience
Doctor M. Blondeel (Leuven, BE)
Abstract Slides Video
Presentation thumbnail
Defibrillation testing at implant of subcutaneous implantable cardioverter defibrillator: weighting propensity score analysis and results from nationwide HONEST cohort
Doctor F. kerkouri (Brest, FR)
Abstract Slides

Access the full session

Session thumbnail
Device therapy (2)

The Event

Event poster

EHRA 2025

31 March 2025 12:30 CET
You may be interested in
thumbnail
Congress Presentation
Subcutaneous ICD therapy across underlying cardiac diseases in paediatric and young adult patients: insights from the european SIDECAR registry
thumbnail
Congress Presentation
Subcutaneous implantable cardioverter-defibrillator in adults with congenital heart disease
thumbnail
Congress Presentation
Comparison of ICD implantation approach in children. The IChilDren study.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources